Literature DB >> 23254483

Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.

Chrysanthos Symeonidis1, Eleni Papakonstantinou, Asimina Galli, Ioannis Tsinopoulos, Asimina Mataftsi, Spyridon Batzios, Stavros A Dimitrakos.   

Abstract

BACKGROUND: The presence of matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetes mellitus (DM) patients and potential correlations with clinical parameters (Schirmer testing, glycosylated hemoglobin-HB(A1C)) were investigated.
METHODS: Tear samples from the right eyes of 27 type 1 DM patients and 17 healthy control subjects were included in this study. The MMP gelatinolytic activity was determined by gelatin zymography analysis using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), while MMP and TIMP concentrations (in ng/ml) were quantified in tears of type 1 diabetic patients and healthy controls, with the use of enzyme-linked immunosorbent assay (ELISA).
RESULTS: MMP-9, TIMP-1, -2 levels, MMP-9/TIMP-1, and MMP-9/TIMP-2 ratios in the patient group were significantly elevated. There was a significant correlation between TIMP-2 and HB(A1C) values, as well as between MMP-2 and MMP-9.
CONCLUSIONS: Significant correlations between TIMP-2 and HB(A1C) and between Schirmer test results and HB(A1C) were revealed. Significant increase in tear MMP and TIMP levels in pediatric type 1 diabetic patients may be suggestive of disease progression and localized pathologic remodelling. Further studies are required in order to ascertain whether MMPs and TIMPs could be employed as indicators of early disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23254483     DOI: 10.1007/s00417-012-2221-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  43 in total

1.  Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.

Authors:  Gomathinayagam Rohini; Ponnalagu Murugeswari; Namperumalsamy Venkatesh Prajna; Prajna Lalitha; Veerappan Muthukkaruppan
Journal:  Cornea       Date:  2007-02       Impact factor: 2.651

Review 2.  Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases.

Authors:  P Borden; R A Heller
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1997       Impact factor: 1.807

3.  Diabetic keratopathy.

Authors:  R O Schultz; D L Van Horn; M A Peters; K M Klewin; W H Schutten
Journal:  Trans Am Ophthalmol Soc       Date:  1981

4.  Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution.

Authors:  A Tuuttila; E Morgunova; U Bergmann; Y Lindqvist; K Maskos; C Fernandez-Catalan; W Bode; K Tryggvason; G Schneider
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

5.  In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta.

Authors:  Guenther Boden; Weiwei Song; Laura Pashko; Karen Kresge
Journal:  Diabetes       Date:  2007-11-19       Impact factor: 9.461

6.  Inflammatory markers in the tears of patients with ocular surface disease.

Authors:  Arantxa Acera; Germán Rocha; Elena Vecino; Isabel Lema; Juan A Durán
Journal:  Ophthalmic Res       Date:  2008-08-07       Impact factor: 2.892

7.  Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Authors:  Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

8.  Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes.

Authors:  John L Fowlkes; Delila M Serra; R Clay Bunn; Kathryn M Thrailkill; Jan J Enghild; Hideaki Nagase
Journal:  Endocrinology       Date:  2003-11-06       Impact factor: 4.736

9.  Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats.

Authors:  Chuan Yang; Ping Zhu; Li Yan; Lihong Chen; Ren Meng; Guojuan Lao
Journal:  J Am Podiatr Med Assoc       Date:  2009 Nov-Dec

10.  Dry eye syndrome in diabetic children.

Authors:  A Akinci; E Cetinkaya; Z Aycan
Journal:  Eur J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 2.597

View more
  6 in total

1.  Intracerebral matrix metalloproteinase 9 in fatal diabetic ketoacidosis.

Authors:  William H Hoffman; Cornelia D Cudrici; Dallas Boodhoo; Alexandru Tatomir; Violeta Rus; Horea Rus
Journal:  Exp Mol Pathol       Date:  2019-04-13       Impact factor: 3.362

Review 2.  Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine.

Authors:  Suzanne Hagan; Eilidh Martin; Amalia Enríquez-de-Salamanca
Journal:  EPMA J       Date:  2016-07-13       Impact factor: 6.543

3.  Potential underlying genetic associations between keratoconus and diabetes mellitus.

Authors:  Kristin M Ates; Amy J Estes; Yutao Liu
Journal:  Adv Ophthalmol Pract Res       Date:  2021-09-04

4.  Tear biomarkers and corneal sensitivity as an indicator of neuropathy in type 2 diabetes.

Authors:  Meera F Iyengar; Luis F Soto; David Requena; Andrea O Ruiz-Alejos; Yvonne Huaylinos; Ricardo Velasquez; Antonio Bernabe-Ortiz; Robert H Gilman
Journal:  Diabetes Res Clin Pract       Date:  2020-04-10       Impact factor: 5.602

5.  Contributions of ocular surface components to matrix-metalloproteinases (MMP)-2 and MMP-9 in feline tears following corneal epithelial wounding.

Authors:  Andrea Petznick; Michele C Madigan; Qian Garrett; Deborah F Sweeney; Margaret D M Evans
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

Review 6.  The Role of Matrix Metalloproteinases in Diabetic Wound Healing in relation to Photobiomodulation.

Authors:  Sandra Matabi Ayuk; Heidi Abrahamse; Nicolette Nadene Houreld
Journal:  J Diabetes Res       Date:  2016-05-23       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.